45880-13-5

Usage

Type of compound

Heterocyclic compound

Structural features

Contains both imidazole and pyridine rings

Potential use

As a ligand in coordination chemistry

Potential use

As a building block in organic synthesis

Metal ion affinity

High affinity for binding to zinc, copper, and nickel ions

Investigation

For its potential use in the development of metal-based pharmaceuticals

Biological activity

Evaluated for cytotoxic effects on cancer cells

Biological activity

Evaluated for antimicrobial properties
This list provides a summary of the key properties and potential applications of 1,2-Dimethyl-1H-imidazo[4,5-c]pyridine based on the information provided.

Upstream product

• 1839-17-4 3-amino-4-(methylamino)pyridine 
• 75-07-0 acetaldehyde 
• 108-24-7 acetic anhydride 
• 1633-41-6 3-nitro-4-methylaminopyridine 
• 13091-23-1 4-chloro-3-nitropyridine 

Downstream Products

• 1207455-23-9 ethyl 2-(4-fluorophenyl)-3-(1-methyl-1H-imidazo[4,5-c]pyridin-2-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate 
• 1207455-22-8 8-(4-fluorophenyl)-9-(1-methyl-1H-imidazo[4,5-c]pyridin-2-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one 

Relevant academic research and scientific papers

METHODS OF USING DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY (ADP-RIBOSE)POLYMERASE (PARP)

Provided herein are methods of treating cancer comprising administering a topoisomerase inhibitor, temozolomide, or a platin in combination with a Compound of Formula (I) or Formula (II), where the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein.

DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)

A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.